Schering-Plough 2Q Revenues: $2.8 billion (+11%)* 2Q Earnings: $237 million (loss of $70 million in 2Q2005)** YTD Revenues: $5.4 billion (+10%) YTD Earnings: $630 million (earnings were $78 million YTD2005) Comments: Sales growth drivers for the quarter included Remicade, Nasonex and Peg-Intron. Remicade sales were up 31% to $307 million; Nasonex sales were up 21% to $242 million; Peg-Intron sales were up 25% to $226 million. R&D spending increased 22% to $539 million i...